<DOC>
	<DOCNO>NCT01244828</DOCNO>
	<brief_summary>This multi-site , open-label fixed-flexible dose long-term study asenapine participant schizophrenia . Participants study consist schizophrenia residual subtype receive high dose/multiple antipsychotic drug , treatment refractory , elderly participant schizophrenia . The treatment period 52 week .</brief_summary>
	<brief_title>Long-term Study Asenapine Participants With Residual Subtype , Receiving Multiple or/and High Dose Drugs , Treatment Refractory Schizophrenia ( P06238 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Minimum age 20 year Participants meet least one following : current diagnosis schizophrenia residual subtype receive treatment 3 antipsychotic drug treatmentrefractory participant schizophrenia 65 year old positive schizophrenia symptom score 3 ( mild ) 1 item positive subscale Positive Negative Syndrome Scale ( PANSS ) baseline Participants Clinical Global ImpressionsSeverity ( CGIS ) score least 4 ( moderately ill ) baseline Uncontrolled , unstable clinically significant medical condition Clinically significant abnormal laboratory , vital sign , physical examination , electrocardiogram ( ECG ) finding Screening Positive pregnancy test Screening , intention become pregnant course study Seizure disorder beyond childhood ( 12 year old young ) History neuroleptic malignant syndrome Allergy sensitivity drug psychotropics antipsychotic Known history currently treat narrow angle glaucoma Parkinson 's disease Diagnosis schizoaffective disorder ; schizophreniform disorder Concurrent psychiatric disorder schizophrenia cod Axis I ; primary diagnosis schizophrenia Diagnosis borderline personality disorder Diagnosis mental retardation organic brain disorder Current ( past 6 month ) substance abuse dependence accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criterion ( exclude nicotine ) Positive drug/alcohol test Screening visit Imminent risk selfharm harm others , Investigator 's opinion Substance induce psychotic disorder behavioral disturbance think due substance abuse Currently involuntary inpatient confinement Use nonapproved drug Japan within 12 week prior inform consent Previously treat asenapine study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>